Analyst Ratings for Keryx Biopharmaceuticals (KERX) [Buys]
KERX Rating Summary
KERX Price Target Summary
- Highest: $15.00 (Brean Capital)
- Lowest: $4.00 (Dawson James)
- Average: $11.60
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$11.60 (+47.2%)
Avg. $ Target:
$11.60 (+47.2%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 12/13/2012 | Maxim Group » Updated 1/28/2013 |
New Coverage | Buy (N/A) |
9.00 (4.00) |
2.77 | 7.88 | 184.48% | Details |
| 11/27/2012 | Dawson James | New Coverage | Market Outperform (N/A) |
4.00 (N/A) |
2.89 | 7.88 | 172.66% | Details |
| 11/8/2012 | JMP Securities » Updated 1/29/2013 |
New Coverage | Market Outperform (N/A) |
8.00 (3.00) |
2.31 | 7.88 | 241.13% | Details |
| 5/10/2012 | Roth Capital » Updated 1/28/2013 |
Upgrade | Buy (N/A) |
15.00 (7.00) |
1.45 | 7.88 | 443.45% | Details |
| 5/10/2012 | Ladenburg Thalmann » Updated 1/29/2013 |
Upgrade | Buy (N/A) |
15.00 (5.00) |
1.45 | 7.88 | 443.45% | Details |
| 5/7/2012 | MLV & Co. » Updated 1/28/2013 |
New Coverage | Buy (N/A) |
15.00 (5.00) |
1.42 | 7.88 | 454.93% | Details |
| 5/17/2011 | Oppenheimer » Updated 2/4/2013 |
New Coverage | Outperform (N/A) |
11.00 (11.00) |
4.89 | 7.88 | 61.15% | Details |
| 9/1/2010 | Stifel Nicolaus » Updated 1/29/2013 |
New Coverage | Buy (N/A) |
13.00 (4.00) |
3.50 | 7.88 | 125.14% | Details |
| 2/9/2004 | Brean Capital » Updated 3/12/2013 |
New Coverage | Buy (N/A) |
15.00 (N/A) |
10.18 | 7.88 | -22.59% | Details |
